Department of Surgery, Washington University School of Medicine, St. Louis, USA
 Mini Review   
								
																AAV-based Fusion Protein Targeting Human VEGFR-2 Domains Shows Promise in Treating Neovascular- Associated Retinal Diseases in Mice 
																Author(s): Yin Cao*             
								
																
						 Neovascular-associated retinal diseases, including age-related macular degeneration and diabetic retinopathy, are leading causes of vision loss 
  worldwide. Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) plays a critical role in angiogenesis, making it an attractive therapeutic 
  target for these diseases. In this study, we developed an Adeno-Associated Virus (AAV)-based fusion protein specifically targeting human VEGFR-2 
  domains to evaluate its efficacy in treating neovascular-associated retinal diseases in mice. The AAV-based fusion protein was designed to consist 
  of a Single-Chain Antibody Fragment (scFv) derived from a high-affinity VEGFR-2 antibody, fused with a potent anti-angiogenic peptide. The scFv 
  component enabled specific binding to VEGFR-2, while the anti-angiogenic peptide aimed to inhibit downstream signaling pathways involved in 
  angiogenesi.. Read More»
						  
																DOI:
								10.37421/2471-2671.2023.9.36															  
Archives of Surgical Oncology received 37 citations as per Google Scholar report